Schwarz Pharma recalls rotigotine transdermal system after crystals form in patch.

Pharmacists are essential in drug therapy management of Parkinson's disease patients and have an opportunity to provide support to both patients and their caregivers.

A new strength of Stalevo, the combination drug from Orion Corp. and Novartis used to treat Parkinson's disease, has been approved by the FDA.

Patch offers new option for early Parkinson's June 4, 2007 By: Heidi Belden, Pharm.D.

FDA has approved Neupro patch designed to treat symptoms of early Parkinson's disease. Consistent and continuous drug delivery over a 24-hour period may prove to be an advantage of this patch.

At the American Academy of Neurology's (AAN) 58th annual meeting in April, new guidelines were released for the diagnosis and treatment of Parkinson's disease (PD). The recommendations were later published in the April 11, 2006, issue of Neurology as four separate practice parameters.

The Food & Drug Administration has approved rasagiline (Azilect, Teva) for the treatment of Parkinson's disease (PD). Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor that blocks the breakdown of dopamine, a chemical that transmits signals between the substantia nigra and other parts of the brain.

Medical practitioners treating Parkinson's disease (PD) tend to focus on controlling patients' movement disorders. So said Monique Giroux, M.D., medical director of the National Parkinson Foundation Center of Excellence at the Cleveland Clinic Foundation. But for the patient, other disease-related symptoms are sometimes just as troubling as the motor disorders.

NEW HOPE FOR PARKINSON'S DISEASE? August 8, 2005 By: Elena Beyzarov, Pharm.D.

Advances in neuroprotection and treatments aimed at preventing motor complications attempt to slow this disabling disorder.

Parcopa (Schwarz Pharma) treats symptoms of Parkinson's disease and parkinsonism, such as shaking, stiffness, and slow movement.